Now available: Small, cost-effective liquid biopsy NGS assay
AmoyDx® HRR Liquid NGS Panel: Detection of mutations in 24 genes
The AmoyDx® HRR Liquid NGS Panel (RUO) is an NGS assay for the qualitative detection of mutations (SNVs, InDels) in 20 HRR genes as well as PTEN, AKT1, PIK3CA and AR on cfDNA from blood plasma. The small, cost-effective panel covers the most important HRR genes including all genes mentioned in the S3 guideline “Prostate cancer”, version 7.0, May 2024 in the context of a PARPi therapy [1].
The library is prepared using the hybrid capture method (ddCAP technology) over two days and the sequence data is analyzed locally by the AmoyDx® NGS Data Analysis System (ANDAS).
For more information, please click here.
Alternatively, you can contact us directly at molpath@zytomed-systems.de
Stay tuned for more liquid biopsy products coming soon.
[1] S3-Leitlinie Prostatakarzinom Version 7.0 – Mai 2024 AWMF-Registernummer: 043-022OL
Further topics
News about the IVDR
The IVDR, in force since May 26, 2022, represents a turning point in the EU-wide harmonization of patient safety. At the same time, it places high demands on us as manufacturers and on you as a user of in vitro diagnostic medical devices to implement the new regulation. We would like to meet this challenge together with you for the benefit of your patients. It is important to us to certify our portfolio of diagnostic solutions in compliance with the IVDR in due time. Therefore, we would like to keep you informed about our progress with the implementation of the IVDR.
S3 guideline for prostate cancer was updated
In May 2024 the S3 guideline "Prostate Cancer" (version 7.0) was updated. For the first time it is recommended to sequence genes involved in homologous recombination repair (HRR), e. g. ATM, BRCA1/2, BRIP1, CDK12, CHEK2, FANCA, HDAC2 and PALB2, before initiating a systemic therapy for castration-resistant prostate cancer (mCRPC).
